Formation Bio launches $600M fund to accelerate AI-powered drug development

Formation Bio is launching a $600 million investment fund to acquire promising experimental medicines and move them through clinical trials faster using artificial intelligence. The New York-based biotech company is betting that the pharmaceutical industry’s biggest problem isn’t finding new drugs. It’s getting them through the costly, time-consuming development process and into patients’ hands.

The new vehicle, called the Formation Bio Drug Development Accelerator Fund, has secured $600 million in capital commitments from research foundations, institutional endowments, hospitals, and philanthropic organizations. The company plans to acquire or license 10 to 15 drug programs over the next three to five years, focusing on treatments already in clinical development.

The announcement marks a significant step for Formation Bio, which is building a different kind of pharmaceutical company around AI, clinical expertise, and a financing structure that allows it to pursue multiple drug programs without funding each one entirely from its own balance sheet.

Unlike traditional biotech startups that often spend years discovering a single treatment, Formation Bio targets existing medicines that have already cleared some early development hurdles. Its strategy centers on acquiring Phase 1 and Phase 2 programs from pharmaceutical companies and smaller biotechs, then using its technology and clinical infrastructure to advance those treatments.

The approach addresses a persistent problem in drug development: promising medicines can remain stuck in pharmaceutical pipelines, often for financial or strategic reasons rather than a lack of scientific potential.

Image credit: Formation Bio

A $600 million bet on fixing the drug development bottleneck

Formation Bio’s new fund takes an unusual approach to financing drug development. Rather than putting every acquired medicine under one corporate umbrella, the company will place each drug program in a separate legal entity, backed by dedicated capital.

Formation Bio will manage the fund through a wholly owned subsidiary and invest alongside its limited partners. Its existing development organization will provide the scientific, clinical, and operational support needed to advance each program.

The structure is intended to reduce duplicate operating costs and give investors exposure to individual drug assets without requiring them to finance an entire biotech company.

“This Fund gives our LPs access to an important and emerging investment category—individual drug assets—through a capital-efficient structure,” said Benjamine Liu, co-founder and CEO of Formation Bio.

For Formation Bio, the arrangement creates another source of financing without relying solely on conventional equity fundraising. It could also provide opportunities to generate returns from successful drug programs without selling the parent company.

The company expects individual programs to reach significant clinical milestones within two to four years of acquisition, depending on their development stage.

Formation Bio’s broader strategy reflects a shift in how AI is being applied to the pharmaceutical industry. Much of the attention surrounding AI in biotech has centered on discovering new molecules. Formation Bio is focusing on what happens after those molecules enter clinical development, where trials, patient recruitment, regulatory requirements, and execution costs can determine whether a promising treatment reaches the market.

The company has already explored that approach through partnerships with major technology and pharmaceutical players. In 2024, Formation Bio teamed up with Sanofi and OpenAI to develop AI tools for drug development, including Muse, a system designed to improve clinical trial patient recruitment.

Formation Bio isn’t alone in the race to use AI to bring new medicines to market. Just yesterday, Anthropic revealed that it had acquired Mithril Medicine, a one-person biotech startup developing treatments for rare forms of muscular dystrophy. The acquisition, completed in July, gives the Claude AI developer a direct foothold in drug research. Anthropic said Mithril’s founder used Claude to coordinate experiments across 11 external laboratories, helping advance a potential treatment from an idea to promising results in mice in less than 18 months.

The two companies are approaching the same problem from different directions. Anthropic is testing how AI can help small research teams discover and develop medicines with fewer resources. Formation Bio is using AI, dedicated investment capital, and shared clinical infrastructure to advance existing drug candidates. Both approaches challenge the traditional economics of pharmaceutical development, where bringing a new medicine to market can take years and cost billions of dollars.

The new fund adds substantial financial capacity to that strategy, giving Formation Bio more opportunities to acquire medicines that established pharmaceutical companies may no longer prioritize.

Still, AI cannot eliminate the scientific uncertainty of clinical trials. Drug candidates must demonstrate safety and efficacy, and many fail despite encouraging early results. Formation Bio has not established that its AI-based approach will consistently improve clinical success rates.

The company aims to use its technology, shared infrastructure, and financial flexibility to develop more treatments more cheaply. Successful programs could eventually be licensed or partnered with larger pharmaceutical companies for commercialization.

For investors, the $600 million fund represents a bet on a different pharmaceutical business model. For Formation Bio, it is a chance to test whether AI can make clinical drug development more efficient at scale.

The bigger question is whether faster execution and smarter financing can turn more overlooked drug candidates into medicines that actually reach patients.